Association Between Proton Pump Inhibitors (PPI) use and Spontaneous Bacterial Peritonitis (SBP) in patients of Cirrhosis with Sepsis

Raja M Waqar  Khan; Shazia  Nisar; Kamran  Ali

doi:10.51253/pafmj.v76iSUPPL-2.6753

Authors

Raja M Waqar Khan Department of General Medicine, Pak Emirates Military Hospital/National University of Medical Sciences (NUMS), Rawalpindi Pakistan
Shazia Nisar Department of General Medicine, Pak Emirates Military Hospital/National University of Medical Sciences (NUMS), Rawalpindi Pakistan
Kamran Ali Department of General Medicine, Pak Emirates Military Hospital/National University of Medical Sciences (NUMS), Rawalpindi Pakistan

DOI:

https://doi.org/10.51253/pafmj.v76iSUPPL-2.6753

Keywords:

Cirrhosis, Peritoneum, Proton Pump Inhibitor, Sepsis, Spontaneous Bacterial Peritonitis.

Abstract

Objective: To find the relationship between Proton Pump Inhibitors (PPIs) use and development of Spontaneous Bacterial Peritonitis (SBP) in patients of cirrhosis with sepsis.

Study Design: Comparative cross-sectional study.

Place and Duration of Study: Medicine Department, Pak Emirate Military Hospital, Rawalpindi Pakistan, from Apr 2020 to May 2021.

Methodology: The patients enrolled were classified as proton pump inhibitor users (Group-A) and non-users (Group-B). The clinical diagnosis of cirrhosis was established by combination of history, examination, laboratory, ultrasound, upper GI endoscopy and by fibro-scan. They were observed and evaluated during the admission for spontaneous bacterial peritonitis and other infections. Chi-square test was used to check for association between variables.

Results: Total number of patients who participated in this study were 103, out of which 53(51.5%) were proton pump inhibitor (PPI) users and 50(48.5%) were non-PPI users. There was an increased chance of bacterial infection among Group-A (38%) than Group-B (p=0.001). Statistically significant difference was also noted for spontaneous bacterial peritonitis (p=0.049) across groups.

Conclusion: Proton pump inhibitor use increased the risk for development of spontaneous bacterial peritonitis in patients of cirrhosis who also had sepsis. Therefore, it is better to avoid proton pump inhibitors in cirrhosis patients with sepsis.

Downloads

Download data is not yet available.

References

1. Elzouki AN, Neffati N, Rasoul F, Abdallah A, Othman M, Waness A. Increased Risk of Spontaneous Bacterial Peritonitis in Cirrhotic Patients Using Proton Pump Inhibitors. GE Port J Gastroenterol 2019; 26(5): 83-89.

https://doi.org/10.1159/000487963

2. Durand C, Willett KC, Desilets AR. Proton pump inhibitor use in hospitalized patients: is overutilization becoming a problem? Clin Med Insights Gastroenterol 2012; 5(3): 65–76.

https://doi.org/10.4137/CGast.S9588

3. Rotman SR, Bishop TF. Proton pump inhibitor use in the U.S. ambulatory setting, 2002–2009. PLoS One 2013; 8(1): e56060.

https://doi.org/10.1371/journal.pone.0056060

4. Lewis JR, Barre D, Zhu K, Ivey KL, Lim EM, Hughes J, et al. Long-term proton pump inhibitor therapy and falls and fractures in elderly women: a prospective cohort study. J Bone Miner Res 2014; 29(7): 2489.

https://doi.org/10.1002/jbmr.2279

5. Thomson AB, Sauve MD, Kassam N, Kamitakahara H. Safety of the long-term use of proton pump inhibitors. World J Gastroenterol 2010; 16(3): 2323–2330.

https://doi.org/10.3748/wjg.v16.i19.2323

6. Miano TA, Reichert MG, Houle TT, MacGregor DA, Kincaid EH, Bowton DL. Nosocomial pneumonia risk and stress ulcer prophylaxis: a comparison of pantoprazole versus ranitidine in cardiothoracic surgery patients. Chest 2009; 136(7): 440–447.

https://doi.org/10.1378/chest.08-1634

7. Barletta JF, Sclar DA. Proton pump inhibitors increase the risk for hospital-acquired Clostridium difficile infection in critically ill patients. Crit Care 2014; 18(3): 714.

https://doi.org/10.1186/s13054-014-0714-7

8. Miozzo SAS, John JA, Appel-da-Silva MC, Dossin IA, Tovo CV, Mattos AA. Influence of proton pump inhibitors in the development of spontaneous bacterial peritonitis. World J Hepatol 2017; 9(35): 1278-1285.

https://doi.org/10.4254/wjh.v9.i35.1278

9. Elzouki AN, Neffati N, Rasoul FA, Abdallah A, Othman M, Waness A. Increased Risk of Spontaneous Bacterial Peritonitis in Cirrhotic Patients Using Proton Pump Inhibitors. GE Port J Gastroenterol 2019; 26(2): 83-89.

https://doi.org/10.1159/000487963

10. Shaikh BA, Shaikh ZA, Shah AH, Kumar A. Determining the Risk of Spontaneous Bacterial Peritonitis due to increase use of Proton Pump Inhibitors among cirrhotic patients with ascites. Pak J Med Sci 2021; 37(4): 1075-1079.

https://doi.org/10.12669/pjms.37.4.3476

11. Marciano S, Diaz JM, Dirchwolf M, Gadano A. Spontaneous bacterial peritonitis in patients with cirrhosis: incidence, outcomes, and treatment strategies. Hepat Med 2019; 11(3): 13-22. https://doi.org/10.2147/HMER.S164250

12. Churpek MM, Snyder A, Sokol S, Pettit NN, Edelson DP. Investigating the impact of different suspicion of infection criteria on the accuracy of quick sepsis-related organ failure assessment, systemic inflammatory response syndrome, and early warning scores. Crit Care Med 2017; 45(1): 1805–1812.

https://doi.org/10.1097/CCM.0000000000002648

13. Kim JH, Lim KS, Min YW, Lee H, Min BH, Rhee PL, et al. Proton pump inhibitors do not increase the risk for recurrent spontaneous bacterial peritonitis in patients with cirrhosis. J Gastroenterol Hepatol 2017; 32(3): 1064–1070.

https://doi.org/10.1111/jgh.13637

14. Dam G, Vilstrup H, Watson H, Jepsen P. Proton pump inhibitors as a risk factor for hepatic encephalopathy and spontaneous bacterial peritonitis in patients with cirrhosis with ascites. Hepatology 2016; 64(3): 1265–1272.

https://doi.org/10.1002/hep.28737

15. Cole H, Pennycook S, Hayes P. The impact of proton pump inhibitor therapy on patients with liver disease. Aliment Pharmacol Ther 2016; 44(11–12): 1213–1223.

https://doi.org/10.1111/apt.13827

16. Janka T, Tornai T, Borbély B, Tornai D, Altorjay I, Papp M et al. Deleterious effect of proton pump inhibitors on the disease course of cirrhosis. Eur J Gastroenterol Hepatol 2020; 32(2): 257–264. https://doi.org/10.1097/MEG.0000000000001499

17. Rajender A, Choudhary P, Mathur S, Bhargava R, Upadhyay S, Nepalia S. Proton pump inhibitor: a risk factor for spontaneous bacterial peritonitis in Indian cirrhotics decompensated with ascites. Int J Res Med Sci 2019; 7(2): 378.

http://dx.doi.org/10.18203/2320-6012.ijrms20190338

18. Min Y, Lim K, Min BH, Gwak GY, Paik Y, Choi M, et al. Proton pump inhibitor use significantly increases the risk of spontaneous bacterial peritonitis in 1965 patients with cirrhosis and ascites: a propensity score matched cohort study. Aliment Pharmacol Ther 2014; 40(6): 695–704.

https://doi.org/10.1111/apt.12875